Literature DB >> 24436274

A centralized recipient database enhances the serologic safety of RBC transfusions for patients with sickle cell disease.

Sarah K Harm1, Mark H Yazer, Grace F Monis, Darrell J Triulzi, James P Aubuchon, Meghan Delaney.   

Abstract

OBJECTIVES: To evaluate the utility of a centralized transfusion service model in preventing the transfusion of incompatible units in patients with sickle cell disease (SCD).
METHODS: The serologic records of transfused patients with SCD were reviewed. The index hospital was where an alloantibody was initially detected.
RESULTS: In total, 150 patients with SCD were evaluated; 66 (44.0%) of 150 were alloimmunized. In 42 (63.6%) of these patients, 1 or more antibodies evanesced. The median number of hospitals visited by patients with SCD for RBC transfusion with 1 or more evanesced antibodies was three (range, one to eight); the median number of nonindex hospitals was two (range, one to seven). Of the patients with evanesced antibodies, 28.6% received transfusions at various nonindex hospitals 20 or more times after the antibody evanesced.
CONCLUSIONS: A centralized database can help identify patients with SCD who have evanesced alloantibodies and prevent issuing incompatible RBC units.

Entities:  

Keywords:  Alloantibody; Centralized transfusion service; Database; Delayed hemolytic reaction; Evanescence; Red blood cell; Sickle cell

Mesh:

Substances:

Year:  2014        PMID: 24436274     DOI: 10.1309/AJCP47QAAXTOZEKJ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  8 in total

Review 1.  Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease.

Authors:  Eric A Gehrie; Paul M Ness; Evan M Bloch; Seema Kacker; Aaron A R Tobian
Journal:  Transfusion       Date:  2017-06-26       Impact factor: 3.157

2.  Integration of red cell genotyping into the blood supply chain: a population-based study.

Authors:  Willy A Flegel; Jerome L Gottschall; Gregory A Denomme
Journal:  Lancet Haematol       Date:  2015-07       Impact factor: 18.959

Review 3.  Would a National Antibody Register contribute to improving patient outcomes?

Authors:  Zachary Powell; Nan Jiang; Rajeshwori Shrestha; Denise E Jackson
Journal:  Blood Transfus       Date:  2021-03-12       Impact factor: 3.443

Review 4.  The transfusion management of beta thalassemia in the United States.

Authors:  Ashutosh Lal; Trisha Wong; Siobán Keel; Monica Pagano; Jong Chung; Aditi Kamdar; Latha Rao; Alan Ikeda; Geetha Puthenveetil; Sanjay Shah; Jennifer Yu; Elliott Vichinsky
Journal:  Transfusion       Date:  2021-08-28       Impact factor: 3.337

5.  Red cell transfusion and alloimmunization in sickle cell disease.

Authors:  Grace E Linder; Stella T Chou
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

6.  American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.

Authors:  Stella T Chou; Mouaz Alsawas; Ross M Fasano; Joshua J Field; Jeanne E Hendrickson; Jo Howard; Michelle Kameka; Janet L Kwiatkowski; France Pirenne; Patricia A Shi; Sean R Stowell; Swee Lay Thein; Connie M Westhoff; Trisha E Wong; Elie A Akl
Journal:  Blood Adv       Date:  2020-01-28

7.  Transfusion service knowledge and immunohaematological practices related to sickle cell disease and thalassemia.

Authors:  R M Fasano; J Branscomb; P A Lane; C D Josephson; A B Snyder; J R Eckman
Journal:  Transfus Med       Date:  2019-02-10       Impact factor: 2.019

8.  Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal.

Authors:  Swee Lay Thein; France Pirenne; Ross M Fasano; Anoosha Habibi; Pablo Bartolucci; Satheesh Chonat; Jeanne E Hendrickson; Sean R Stowell
Journal:  Haematologica       Date:  2020-02-06       Impact factor: 11.047

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.